SEC Form 4 · accession 0001140361-17-038271
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A. Macke
Other
Period of report
Oct 10, 2017
Accepted (ET)
Oct 11, 2017 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $4.07 | holding | — | — | — | — | Feb 1, 2023 | ADSs | 7,500 | 7,500 | D |
| Stock Option (right to buy)F4 | $7.36 | holding | — | — | — | — | Dec 12, 2023 | ADSs | 20,000 | 20,000 | D |
| Stock Option (right to buy)F5 | $16.30 | holding | — | — | — | — | Dec 11, 2024 | ADSs | 50,000 | 50,000 | D |
| Stock Option (right to buy)F6 | $14.35 | holding | — | — | — | — | Dec 10, 2025 | ADSs | 35,000 | 35,000 | D |
| Stock Option (right to buy)F7 | $10.40 | holding | — | — | — | — | Dec 14, 2026 | ADSs | 65,000 | 65,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- F2Includes (a) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/12/2013, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (c) 15,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (d) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- F3Options became exercisable as to 1,875 ADSs on each of the first four anniversaries after the 02/01//2013 grant date.
- F4Options become exercisable as to 5,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date.
- F5Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- F6Options become exercisable as to 8,750 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- F7Options become exercisable as to 16,250 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Remarks
This filing constitutes a Form 4 exit filing for the Reporting Person as the Reporting Person is no longer subject to Section 16 under the Securities Exchange Act of 1934.